Publications by authors named "H Ohmura"
Background: Pembrolizumab, an immune checkpoint inhibitor (ICI), shows significant survival benefits in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), but its efficacy in microsatellite-stable (MSS) mCRC is limited. Although ICIs are effective in tumor mutational burden-high (TMB-H) solid tumors, the impact on MSS-TMB-H mCRC, a rare subset within MSS mCRC, remains unclear.
Materials And Methods: We conducted a retrospective analysis using clinical and genomic data from the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) repository in Japan.
Introduction: Protection of horse welfare during transport is crucial. The aim of this study was to determine the effect of head and neck restraint on behavior and airway bacteria.
Methods: In a randomized crossover study, six healthy Thoroughbreds were transported by road for 22 h in an individual bay with tight head restraint (50 cm short-rope) or loose head restraint (95 cm long-rope).
A 75-year-old man diagnosed with esophageal cancer and lung metastasis received a combination of fluorouracil, cisplatin, and pembrolizumab. During pembrolizumab maintenance therapy, lymphoproliferative lesions at the lips and mouth and multiple lymph node swellings appeared. Histologically, Epstein-Barr virus (EBV)-encoded RNA was positive, and EBV-DNA was detected in the blood.
View Article and Find Full Text PDFArticle Synopsis
- Researchers studied immune cells in patients with esophageal squamous cell cancer undergoing immune checkpoint blockade (ICB) therapy to understand what makes the treatment effective.
- They found a specific group of CD39PD-1CD8 T cells, particularly the TCF1 subset known as precursor exhausted T (CD39 Tpex) cells, which were linked to better treatment outcomes.
- These CD39 Tpex cells are mostly found in the tumor's supportive tissue and are recruited from tertiary lymphoid structures (TLS), indicating a significant role in the immune response against tumors during ICB therapy.
Article Synopsis
- - The study analyzed records of 47 patients with primary cardiac tumors from Kyushu University Hospital, finding that 13 (28%) were diagnosed with malignant tumors, including various sarcomas and lymphomas, highlighting the rarity of such cases.
- - Cardiovascular complications were prevalent, with 77% of patients experiencing issues like heart dysfunction, arrhythmias, and right heart failure, often linked to the aggressive multimodal treatment involving surgery, chemotherapy, and radiotherapy.
- - Two cases exemplified severe complications: one patient faced significant heart failure post-treatment, while another developed a heart block due to tumor placement, indicating the need for careful management to improve patient outcomes.